Emerging Markets To Drive Sales Of Antiretrovirals

BMI View: While the number of HIV infections in the major pharmaceutical markets represents a relatively small proportion of the globally infected population, emerging markets will increasingly drive growth in this therapeutic class. BMI believes that despite social, political and economic pressures continuing to constrain profitability of HIV medicines, governments are likely to place a greater emphasis on the socio-economic benefits of a healthy population.

To read the full article, please choose one of the following options: